(Q33426556)

26 July 2017

title

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (English)

1 reference

26 July 2017

0 references

Andrew Gabrielson

1

1 reference

26 July 2017

Anteneh A Tesfaye

2

1 reference

26 July 2017

John L Marshall

3

1 reference

26 July 2017

Michael J Pishvaian

4

1 reference

26 July 2017

Brandon Smaglo

5

1 reference

26 July 2017

Reena Jha

6

1 reference

26 July 2017

Karen Dorsch-Vogel

7

1 reference

26 July 2017

Hongkun Wang

8

1 reference

26 July 2017

Aiwu Ruth He

9

1 reference

26 July 2017

publication date

8 October 2015

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

published in

1 reference

26 July 2017

volume

76

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

1073-1079

1 reference

Creative Commons Attribution 4.0 International

26 July 2017

copyright license

start time

8 October 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Role of PARP inhibitors in cancer biology and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

A review of PARP inhibitors: from bench to bedside

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Mystery of DNA repair: the role of the MRN complex and ATM kinase in DNA damage repair

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Sorafenib in advanced hepatocellular carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Chemoembolization and bland embolization: a critical appraisal

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Telomeres, stem cells, senescence, and cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

21 June 2018

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma associated with hepatitis viral infection.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4612326

Sorafenib in liver cancer--just the beginning

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-015-2852-2

A modification of Simon's optimal design for phase II trials when the criterion is median sample size

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-015-2852-2

Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00280-015-2852-2

Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma

1 reference

12 December 2020

Cancer chromosomes in crisis

1 reference

12 December 2020

Multimodality treatment of hepatocellular carcinoma

1 reference

12 December 2020

Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers

1 reference

12 December 2020

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

12 December 2020

10.1007/S00280-015-2852-2

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference